Fridriksdottir Hafrun
Known title: Executive VP, Global R&DCIK: 0001561458
Associated companies
this person other insiders at TEVA
Transaction History
| TEVA | ▼ Sell | Open Market | 130,000 | $1.1M | 5/17/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 8,941 | $66K | 3/7/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 23,764 | — | 3/5/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 51,488 | — | 3/4/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 18,905 | — | 3/4/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 6,618 | $50K | 3/4/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 18,020 | $135K | 3/4/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 7,590 | $62K | 2/28/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 21,682 | — | 2/28/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 6,116 | $55K | 2/9/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 16,121 | — | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.